SurModics of Minnesota announced the completion of a License and Development Agreement with Roche / Genentech Inc for the use of SurModics’ proprietary microparticulate drug delivery technology. The deal provides for Roche/Genentech to exclusively develop and commercilaize a sustained drug delivery formulation of Lucentis (ranibizumab).